FCMI
KNTE

Foresite Capital Management IV’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Foresite Capital Management IV’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,671,643
Closed -$25.7M – 5
2024
Q1 		$25.7M Hold
9,671,643
– – 13% 3
2023
Q4 		$22.9M Hold
9,671,643
– – 11.58% 3
2023
Q3 		$13.5M Hold
9,671,643
– – 7.52% 5
2023
Q2 		$29.3M Hold
9,671,643
– – 14.41% 3
2023
Q1 		$60.4M Hold
9,671,643
– – 31.36% 1
2022
Q4 		$59M Hold
9,671,643
– – 25.2% 1
2022
Q3 		$116M Hold
9,671,643
– – 37.17% 1
2022
Q2 		$122M Hold
9,671,643
– – 32.84% 1
2022
Q1 		$109M Hold
9,671,643
– – 30.47% 1
2021
Q4 		$171M Hold
9,671,643
– – 35.26% 1
2021
Q3 		$223M Hold
9,671,643
– – 32.78% 1
2021
Q2 		$225M Hold
9,671,643
– – 30.43% 1
2021
Q1 		$301M Hold
9,671,643
– – 36.1% 1
2020
Q4 		$385M Buy
+9,671,643
New +$388M 41.79% 1

Foresite Capital Management IV's KNTE Position: Q2 2024 in Review

Foresite Capital Management IV sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 9,671,643 shares — an estimated $25.7M sold.

Foresite Capital Management IV first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $385M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Foresite Capital Management IV reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Foresite Capital Management IV sold 9,671,643 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $25.7M.
  • Foresite Capital Management IV first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Foresite Capital Management IV's Kinnate Biopharma Inc. Common Stock position peaked at $385M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Foresite Capital Management IV's 13F filing for Q2 2024, filed 13 Aug 2024.